Twitter
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • The CEO about the future
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How K.O.S is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • Equity research & presentations
    • Financial calendar
    • The share
    • Corporate Governance
    • Company description
    • Owner information
    • Rights Issue 2022
  • FAQ
  • Svenska
Menu
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • The CEO about the future
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How K.O.S is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • Equity research & presentations
    • Financial calendar
    • The share
    • Corporate Governance
    • Company description
    • Owner information
    • Rights Issue 2022
  • FAQ
  • Svenska

Category: Uncategorized

  • Uncategorized

    New analysis from Västra Hamnen after the completion of the rights issue

  • Uncategorized

    Chordate Medical Holding ABs (publ) set-off share issue is now registered

  • Uncategorized

    Chordate Medical Holding AB (publ) announces last day of trading in paid subscription shares (BTA)

  • Uncategorized

    Chordate Medical Holding AB’s (publ) rights issue was subscribed to approximately 72 percent

  • Uncategorized

    Chordate granted new patent by the European Patent Office

  • Uncategorized

    Subscription period in Chordate Medical Holding ABs (publ) rights issue ends on 9th January

  • Uncategorized

    Invitation to live investor meeting with Chordate Medical 29 December at 14:00

  • Uncategorized

    Subscription period begins in Chordate Medical Holding ABs (publ) rights issue

  • Uncategorized

    Chordate Medical Holding AB (publ) obtains additional subscription and underwriting commitments

  • Uncategorized

    Chordate Medical Holding AB (publ) publishes prospectus in connection with the rights issue

1 2 3 … 5

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).

Press releases

Chordate Medical Holding ABs (publ) set-off share issue is now registered

24 January 2023

Chordate Medical Holding AB (publ) announces last day of trading in paid subscription shares (BTA)

20 January 2023

Chordate Medical Holding AB (publ) carries out a directed set-off share issue to underwriters in the completed rights issue

18 January 2023

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
SAVE & ACCEPT